Trial Profile
A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Zotiraciclib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Lee Pharmaceuticals
- 23 Sep 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 18 Nov 2018 New trial record